FLAVIO TARASOUTCHI

(Fonte: Lattes)
Índice h a partir de 2011
14
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação, Hospital das Clínicas, Faculdade de Medicina
LIM/64, Hospital das Clínicas, Faculdade de Medicina - Líder

Filtros

Limpar filtros

Configurações

search.filters.applied.f.dateIssued: 2015 × Tipo de produção: article ×

Resultados de Busca

Agora exibindo 1 - 8 de 8
  • article 0 Citação(ões) na Scopus
    Percutaneous Treatment of Mitral Paraprosthetic Regurgitation: an Alternative to Surgery
    (2015) SAMPAIO, Roney Orismar; OLIVEIRA, Alessandra Gomes de; MIRANDA, George Barreto; LEMOS NETO, Pedro Alves; VIEIRA, Marcelo Luiz Campos; TARASOUTCHI, Flavio
  • article 2 Citação(ões) na Scopus
    Patient Management with Metallic Valve Prosthesis during Pregnancy and Postpartum Period
    (2015) GARCEZ, Juliane Dantas Seabra; ROSA, Vitor Emer Egypto; LOPES, Antonio Sergio de Santis Andrade; ACCORSI, Tarso Augusto Duenhas; FERNANDES, Joao Ricardo Cordeiro; POMERANTZEFF, Pablo Maria; AVILA, Walkiria Samuel; TARASOUTCHI, Flavio
    Prosthetic thrombosis is a rare complication, but it has high mortality and morbidity. Young women of childbearing age that have prosthetic heart valves are at increased risk of thrombosis during pregnancy due to changes in coagulation factors. Anticoagulation with adequate control and frequent follow-up if pregnancy occurs must be performed in order to prevent complications related to anticoagulant use. Surgery remains the treatment of choice for prosthetic heart valve thrombosis in most clinical conditions. Patients with metallic prosthetic valves have an estimated 5% risk of thrombosis during pregnancy and maternal mortality of 1.5% related to the event. Anticoagulation with vitamin K antagonists during pregnancy is related to varying degrees of complications at each stage of the pregnancy and postpartum periods. Warfarin sodium crosses the placental barrier and when used in the first trimester of pregnancy is a teratogenic agent, causing 1-3% of malformations characterized by fetal warfarin syndrome and also constitutes a major cause of miscarriage in 10-30% of cases. In the third trimester and at delivery, the use of warfarin is associated with maternal and neonatal bleeding in approximately 5 to 15% of cases, respectively. On the other hand, inadequate anticoagulation, including the suspension of the oral anticoagulants aiming at fetal protection, carries a maternal risk of about 25% of metallic prosthesis thrombosis, particularly in the mitral valve. This fact is also due to the state of maternal hypercoagulability with activation of coagulation factors V, VI, VII, IX, X, platelet activity and fibrinogen synthesis, and decrease in protein S levels. The Registry of Pregnancy and Cardiac Disease (ROPAC), assessing 212 pregnant women with metal prosthesis, showed that prosthesis thrombosis occurred in 10 (4.7%) patients and maternal hemorrhage in 23.1%, concluding that only 58% of patients with metallic prosthesis had a complication-free pregnancy(1-7).
  • article 3 Citação(ões) na Scopus
    Trombo Gigante em Átrio Esquerdo com Vascularização Coronária Dupla
    (2015) CIAMBELLI, Giuliano Serafino; BAPTISTA, Mariana Lins; ROSA, Vitor Emer Egypto; LOPES, Antonio Sergio de Santis Andrade; ACCORSI, Tarso Augusto Duenhas; TARASOUTCHI, Flavio
  • article 3 Citação(ões) na Scopus
    Low-Flow Aortic Stenosis and Reduced Ejection Fraction: New Insights
    (2015) ROSA, Vitor Emer Egypto; ACCORSI, Tarso Augusto Duenhas; FERNANDES, Joao Ricardo Cordeiro; LOPES, Antonio Sergio de Santis Andrade; SAMPAIO, Roney Orismar; TARASOUTCHI, Flavio
  • article 7 Citação(ões) na Scopus
    Heart Transplant in Patients with Predominantly Rheumatic Valvular Heart Disease
    (2015) ROSA, Vitor E. E.; LOPES, Antonio S. S. A.; ACCORSI, Tarso A. D.; FERNANDES, Joao Ricardo C.; SPINA, Guilherme S.; SAMPAIO, Roney O.; BACAL, Fernando; TARASOUTCHI, Flavio
    Background and aim of the study: International records indicate that only 2.6% of patients with heart transplants have valvular heart disease. The study aim was to evaluate the epidemiological and clinical profile of patients with valvular heart disease undergoing heart transplantation. Methods: Between 1985 and 2013, a total of 569 heart transplants was performed at the authors' institution. Twenty patients (13 men, seven women; mean age 39.5 +/- 15.2 years) underwent heart transplant due to structural (primary) valvular disease. Analyses were made of the patients' clinical profile, laboratory data, echocardiographic and histopathological data, and mortality and rejection. Results: Of the patients, 18 (90%) had a rheumatic etiology, with 85% having undergone previous valve surgery (45% had one or more operations), and 95% with a normal functioning valve prosthesis at the time of transplantation. Atrial fibrillation was present in seven patients (35%), while nine (45%) were in NYHA functional class IV and eight (40%) in class III. The indication for cardiac transplantation was refractory heart failure in seven patients (35%) and persistent NYHA class III/IV in ten (50%). The mean left ventricular ejection fraction (LVEF) was 26.6 +/- 7.9%. The one-year mortality was 20%. Histological examination of the recipients' hearts showed five (27.7%) to have reactivated rheumatic myocarditis without prior diagnosis at the time of transplantation. Univariate analysis showed that age, gender, LVEF, rheumatic activity and rejection were not associated with mortality at one year. Conclusion: Among the present patient cohort, rheumatic heart disease was the leading cause of heart transplantation, and a significant proportion of these patients had reactivated myocarditis diagnosed in the histological analyses. Thus, it appears valid to investigate the existence of rheumatic activity, especially in valvular cardiomyopathy with severe systolic dysfunction before transplantation.
  • article 12 Citação(ões) na Scopus
    Desempenho de Escores de Risco Cirúrgico para Prever Mortalidade após Implante Transcateter de Valva Aórtica
    (2015) SILVA, Leonardo Sinnott; CARAMORI, Paulo Ricardo Avancini; NUNES FILHO, Antonio Carlos Bacelar; KATZ, Marcelo; GUARAGNA, Joao Carlos Vieira da Costa; LEMOS, Pedro; LIMA, Valter; ABIZAID, Alexandre; TARASOUTCHI, Flavio; BRITO JR., Fabio S. de
    Background: Predicting mortality in patients undergoing transcatheter aortic valve implantation (TAVI) remains a challenge. Objectives: To evaluate the performance of 5 risk scores for cardiac surgery in predicting the 30-day mortality among patients of the Brazilian Registry of TAVI. Methods: The Brazilian Multicenter Registry prospectively enrolled 418 patients undergoing TAVI in 18 centers between 2008 and 2013. The 30-day mortality risk was calculated using the following surgical scores: the logistic EuroSCORE I (ESI), EuroSCORE II (ESII), Society of Thoracic Surgeons (STS) score, Ambler score (AS) and Guaragna score (GS). The performance of the risk scores was evaluated in terms of their calibration (Hosmer-Lemeshow test) and discrimination [area under the receiver-operating characteristic curve (AUC)]. Results: The mean age was 81.5 +/- 7.7 years. The CoreValve (Medtronic) was used in 86.1% of the cohort, and the transfemoral approach was used in 96.2%. The observed 30-day mortality was 9.1%. The 30-day mortality predicted by the scores was as follows: ESI, 20.2 +/- 13.8%; ESII, 6.5 +/- 13.8%; STS score, 14.7 +/- 4.4%; AS, 7.0 +/- 3.8%; GS, 17.3 +/- 10.8%. Using AUC, none of the tested scores could accurately predict the 30-day mortality. AUC for the scores was as follows: 0.58 [95% confidence interval (CI): 0.49 to 0.68, p = 0.09] for ESI; 0.54 (95% CI: 0.44 to 0.64, p = 0.42) for ESII; 0.57 (95% CI: 0.47 to 0.67, p = 0.16) for AS; 0.48 (95% IC: 0.38 to 0.57, p = 0.68) for STS score; and 0.52 (95% CI: 0.42 to 0.62, p = 0.64) for GS. The Hosmer-Lemeshow test indicated acceptable calibration for all scores (p > 0.05). Conclusions: In this real world Brazilian registry, the surgical risk scores were inaccurate in predicting mortality after TAVI. Risk models specifically developed for TAVI are required.
  • article 1 Citação(ões) na Scopus
    Mitral annulus morphologic and functional analysis using real time tridimensional echocardiography in patients submitted to unsupported mitral valve repair
    (2015) GUEDES, Marco Antonio Vieira; POMERANTZEFF, Pablo Maria Alberto; BRANDAO, Carlos Manuel de Almeida; VIEIRA, Marcelo Luiz Campos; TARASOUTCHI, Flavio; SPINOLA, Pablo da Cunha; JATENE, Fabio Biscegli
    Introduction: Mitral valve repair is the treatment of choice to correct mitral insufficiency, although the literature related to mitral valve annulus behavior after mitral repair without use of prosthetic rings is scarce. Objective: To analyze mitral annulus morphology and function using real time tridimensional echocardiography in individuals submitted to mitral valve repair with Double Teflon technique. Methods: Fourteen patients with mitral valve insufficiency secondary to mixomatous degeneration that were submitted to mitral valve repair with the Double Teflon technique were included. Thirteen patients were in FC III/IV. Patients were evaluated in preoperative period, immediate postoperative period, 6 months and 1 year after mitral repair. Statistical analysis was made by repeated measures ANOVA test and was considered statistically significant P<0.05. Results: There were no deaths, reoperation due to valve dysfunction, thromboembolism or endocarditis during the study. Posterior mitral annulus demonstrated a significant reduction in immediate postoperative period (P<0.001), remaining stable during the study, and presents a mean of reduction of 25.8% comparing with preoperative period. There was a significant reduction in anteroposterior and mediolateral diameters in the immediate postoperative period (P<0.001), although there was a significant increase in mediolateral diameter between immediate postoperative period and 1 year. There was no difference in mitral internal area variation over the cardiac cycle during the study. Conclusion: Segmentar annuloplasty reduced the posterior component of mitral annulus, which remained stable in a 1-year-period. The variation in mitral annulus area during cardiac cycle remained stable during the study.
  • article 11 Citação(ões) na Scopus
    EuroSCORE Models in a Cohort of Patients with Valvular Heart Disease and a High Prevalence of Rheumatic Fever Submitted to Surgical Procedures
    (2015) CASALINO, Ricardo; TARASOUTCHI, Flavio; SPINA, Guilherme; KATZ, Marcelo; BACELAR, Antonio; SAMPAIO, Roney; RANZANI, Otavio T.; POMERANTZEFF, Pablo M.; GRINBERG, Max
    Objectives Epidemiological differences can be found between Brazilian and European valvular heart disease patients. The prevalence of heart valve diseases due to rheumatic disease is significantly higher in the Brazilian compared with the European population. Therefore, they could have different risks during and after cardiac surgery. The aim of this study was to evaluate the applicability of the additive and logistic EuroSCORE and EuroSCORE II in a cohort of high-risk patients with valvular heart disease of predominantly rheumatic aetiology submitted to surgery. Methods Between 1 February and 30 December 2009, 540 consecutive patients scheduled for valvular heart surgery were included in this study. In this set of patients, we examined the performance of the additive, logistic, and EuroSCORE II models for predicting in-hospital mortality. Calibration of each model was assessed by comparing predicted and observed in-hospital mortality and by the goodness of fit of the Hosmer-Lemeshow chi-square test. Discrimination performance of the model was evaluated with the receiver operating characteristic (ROC) curve analysis. Results The mean age was 56 +/- 16 years, 50.6% were female, and the mortality rate was 16.0% (6.0% in elective surgery and 34.0% in emergency/urgency surgery). Mortality rates were estimated according to the additive and logistic EuroSCORE and EuroSCORE II at 6.1%, 8.7%, and 4.3%, respectively. The AUC was 0.76 (95% confidence interval [95% CI] 0.70-0.81) for the additive EuroSCORE, 0.76 (95% CI 0.70-0.81) for the logistic EuroSCORE and 0.81 (95% CI 0.76-0.86) for EuroSCORE II. Hosmer-Lemeshow goodness-of-fit statistics were P = 0.52, P = 0.07, and P = 0.12 for additive, logistic EuroSCORE, and EuroSCORE II. Conclusions In this cohort of Brazilian patients with valvular heart disease submitted to surgical procedure, the EuroSCORE models had a good discriminatory capacity; however, the calibration was compromised because of an underestimation of the mortality rate.